SCHEMBL653571

SCHEMBL653571

CC(=O)Nc1ccc(N=C2NC(=O)C(=Cc3cnc(NC(=O)CCC(=O)O)s3)S2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.42
KMT2A Q03164 8/20 0.42
MAPT P10636 5/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 6/20 0.42
PTPN7 P35236 3/20 0.42
DUSP3 P51452 3/20 0.42
PTPN12 Q05209 3/20 0.42
PTPN22 Q9Y2R2 3/20 0.42
PTPN5 P54829 1/20 0.42
PTPN11 Q06124 1/20 0.42
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
HPGD P15428 1/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
AURKA O14965 2/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653570 1.00 MEN1 (0.42) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL650807 0.90 SYK (0.48) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL649726 0.90 SYK (0.48) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL653260 0.89 NPC1 (0.50) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL653261 0.89 NPC1 (0.50) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL651434 0.89 POLB (0.54) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL651435 0.89 POLB (0.54) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL649045 0.89 MEN1 (0.46) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL649044 0.89 MEN1 (0.46) MEN1KMT2AMAPTLMNAPOLB
SCHEMBL653119 0.88 MAPT (0.52) MEN1KMT2AMAPTPOLBPTPN7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MEN1 1406/4885KMT2A 3437/4885MAPT 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.